HOME >> BIOLOGY >> NEWS
Blood stem cells carry targeted genes

Researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have genetically altered human blood stem cells to selectively activate genes in developing immune cells. Results of the research in mice, published in the January 15 issue of Blood, shows it's possible to transfer genes into stem cells and activate the immune system to fight cancer and enhance transplantation.

"Blood stem cells represent an important target for the treatment of a variety of blood and immune disorders, so our ability to engineer them to selectively stimulate immune responses opens up new possibilities for gene therapy," says Linzhao Cheng, Ph.D., assistant professor of oncology at the Johns Hopkins Kimmel Cancer Center and director of the study.

Using a gene known to produce a fluorescent protein, scientists transferred it into human adult and cord blood stem cells and injected the cells into immune-compromised mice. The gene transfer into the stem cells was accomplished via a lentivirus, genetically engineered to be safe, with coded instructions for the gene to turn on in a specific type of cell.

Since blood stem cells differentiate and develop into all blood and immune system cells, all descendants of the stem cells had the fluorescent protein gene. However, the gene turns on only when the stem cell developed into one type of immune cell, called an antigen-presenting cell (APC). APCs play a central role in controlling immune system responses.

"The ability to deliver a gene in a stem cell and then have it expressed in one specific type of cell should provide a new way to achieve targeted gene therapy," says Cheng.

Six mice were transplanted with the fluorescent gene made specific for APCs. After 10 weeks, all produced the fluorescent protein in an average of 56 percent of the transplanted cells, and exclusively in APCs. Five control mice were transplanted with the fluorescent gene made universal for all cells and pr
'"/>

Contact: Amy Heaps
heapsam@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
8-Jan-2002


Page: 1 2

Related biology news :

1. Blood pressure hormone may inhibit growth of lung cancer
2. Blood tests identify patients on dialysis at high risk for death from cardiovascular disease
3. Blood banking systems improving in China, more progress needed
4. Blood proteins tied to inflammation
5. Bloodworms way with copper likely provides paradigm for new materials
6. Blood markers may reflect newborns potential of contracting HIV
7. Blood vessels trigger development of the pancreas
8. Blood vessels found to signal chain of destruction in bone diseases
9. Blood markers associated with autism and mental retardation
10. Blood test for diagnosing schizophrenia
11. Blood pressure-lowering DASH diet also reduces homocysteine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
Breaking Biology Technology:
Cached News: